Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...
Drug Store News18h
Novo Nordisk to cap insulin prices in Minnesota settlement
The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...
LLY Beats Q4 Earnings & Sales, Gives 2025 EPS Guidance
This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-qua ...
Newsable Asianet News on MSN21h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
BioSpace21h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...